A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of AP23573, an mTOR Inhibitor, in Patients With Refractory or Advanced Malignancies.

Trial Profile

A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of AP23573, an mTOR Inhibitor, in Patients With Refractory or Advanced Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2014

At a glance

  • Drugs Ridaforolimus (Primary)
  • Indications Lymphoma; Myeloma
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Jul 2011 Additional lead trial centers identified and company added in association field as reported by ClinicalTrials.gov.
    • 02 Aug 2007 Drug name changed from AP 23573 to deforolimus (INN).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top